Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7122474 | 1.00 | HRH3 (0.41) | HRH3CHRM5ADRA2C | |
| SCHEMBL9379533 | 0.98 | HRH3 (0.42) | HRH3CHRM5ADRA2C | |
| SCHEMBL13002 | 0.81 | HRH3 (0.47) | HRH3CHRM5ADRA2C | |
| SCHEMBL12385 | 0.79 | HRH3 (0.49) | HRH3CHRM5ADRA2C | |
| SCHEMBL13215 | 0.79 | HRH3 (0.49) | HRH3CHRM5ADRA2C | |
| SCHEMBL31448266 | 0.76 | HRH3 (0.44) | HRH3 | |
| SCHEMBL4440646 | 0.75 | GNAI3 (0.42) | HRH3CHRM5ADRA2C | |
| SCHEMBL7124323 | 0.74 | ALDH1A1 (0.42) | HRH3CHRM5ADRA2C | |
| SCHEMBL7124332 | 0.74 | ALDH1A1 (0.42) | HRH3CHRM5ADRA2C | |
| SCHEMBL9192549 | 0.73 | ACHE (0.45) | HRH3CHRM5ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | DMPK, ADK, MAP3K20 | HRH3 3137/4885CHRM5 3685/4885ADRA2C 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.